Safety and efficiency of a presbyopia-correcting bifocal intracorneal implant in emmetropic patients: 6-month results

Session Details

Session Title: Corneal Presbyopia & Astigmatism Correction

Session Date/Time: Tuesday 17/09/2019 | 16:30-18:00

Paper Time: 16:36

Venue: Free Paper Forum: Podium 3

First Author: : C.Lwowski GERMANY

Co Author(s): :    M. Herzog   K. Petermann   E. Hemkeppler   R. Forster   M. Böhm   T. Kohnen              

Abstract Details

Purpose:

To evaluate the safety and efficiency of a bifocal, presbyopia correcting corneal implant in emmetropic patients 6 months after implantation in the non-dominant eye.

Setting:

Univesity Hospital Frankfurt, Germany

Methods:

In this propective trial 20 emmetropic patients were included for implantation of a bifocal corneal implant (Flexivue MicrolensTM, Presbia, CA, USA) in the non-dominant eye (study eye). Follow-up took place 1 week and 1, 3 and 6 months postoperative. Main outcome measures where corrected and uncorrected distant, intermediate and near visual acuity (UDVA, UIVA, UNVA, CDVA, DCIVA, DCNVA; logMAR) of both eyes and subjective optical quality.

Results:

Postoperative the study eyes gained significant UNVA compared to the dominant eye (0.21±0.2, 0.17±0.13, 0.16±0.11, 0.16±0.09 vs 0.47±0.15, 0.47±0.17, 0.46±0.09, 0.39±0.2; p<0.001) but lost UDVA simultaneously (0.32±0.15, 0.22±0.15, 0.19±0.14, 0.24±0.17 vs -0.08±0.08, -0.09±0.13, -0.1±0.08, -0.11±0.11; p<0.001). The binocular distant visual acuity was not affected. Most patients reported to be largely spectacle independent at the 6 months visit. Two patients requested a explantation mostly due to optical phenomena.

Conclusions:

The Flexivue MicrolensTM offers spectacle independency to a great extend in most emmetropic patients after 6 months by increasing near visual acuity without reducing binocular distant visual acuity.

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented